Bayer Reports Submission of MAA to the EMA for Pre-Filled Syringe to Administer Eylea (aflibercept solution for intravitreal injection)
Shots:
- Bayer has applied for the approval to the EMA for its pre-filled syringe to administer Eylea for five retinal indications including neovascular wet AMD- macular edema following RVO- DME- myopic CNV
- Following the state-of-the-art pre-filled syringe of Eylea is approved- it would be the new option for treatment requiring fewer steps to prepare IVT
- Eylea (solution for injection) is a recombinant fusion protein- consisting of human VEGF receptors 1&2 extracellular domains fused to the Fc portion of human IgG1- formulated as an iso-osmotic solution for IVT and has received the FDA’s approval as a prefilled syringe
Click here to read full press release/ article | Ref: Bayer | Image: Phys
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com